Psilocybin-assisted therapy in Canada: how legal access works

Is psilocybin therapy legal in Canada? Only in narrow, supervised ways. Health Canada says that production, sale and possession of magic mushrooms are illegal, and that there are no approved therapeutic products containing psilocybin in Canada or elsewhere (Health Canada). Legal access therefore means one of a few exceptions, each of which runs through a regulated health care practitioner or researcher and Health Canada.

This guide maps those exceptions as they stood on 4 October 2026. It explains what each one requires, what it does not allow, and what is unsettled. Each claim comes from a government page we opened. It does not recommend any clinic, provider, campaign or product, and it is not a guide to getting psilocybin.

Is psilocybin-assisted therapy legal in Canada?

Psilocybin and psilocin are controlled under the Controlled Drugs and Substances Act (CDSA). Health Canada says that activities with magic mushrooms, psilocybin and psilocin, including sale, possession and production, are illegal unless Health Canada authorizes them, for example through a licence, an exemption or the regulations (Health Canada).

Health Canada also says the evidence for psilocybin is still limited: some early trials have shown promising results, but it is an unapproved drug whose safety, efficacy and quality it has not assessed (Health Canada). So “psilocybin-assisted therapy” in Canada is, for now, an experimental treatment that is available only under one of the authorized routes below. For the evidence itself, see our reading of the depression trials.

What are the lawful routes to psilocybin therapy in Canada?

Health Canada’s psilocybin page names three pathways. In its words, individuals may be able to legally access psilocybin in some circumstances, with the support of a regulated health care practitioner (Health Canada). The table summarizes them. Details follow, and the dates matter: the page was last modified on 20 October 2026, after the regulatory change described below, but apart from one sentence on clinical trials it reads as it did before that change.

How do clinical trials work as a route to psilocybin?

Health Canada calls clinical trials the most appropriate way to advance research with unapproved drugs such as psilocybin and says they should be the first legal route pursued by people seeking therapeutic access (Health Canada). That does not make a trial a service. It is research with entry rules, and being in one does not mean receiving a treatment of any proven benefit.

What does a trial require?

A sponsor files a clinical trial application under Part C, Division 5 of the Food and Drug Regulations. The application includes a protocol, an informed consent form, an Investigator’s Brochure and chemistry and manufacturing information. The drug must be made to Good Manufacturing Practices, and a research ethics board must approve the trial independently of Health Canada (Health Canada notice, 2022).

Because psilocybin is also a controlled substance, researchers needed separate authorization under the CDSA regime. Health Canada’s 2022 notice describes a No Objection Letter followed by an authorization under Part J of the Food and Drug Regulations (Health Canada notice, 2022). Part J was repealed on 1 October 2026. Health Canada’s psilocybin page, updated on 20 October 2026, now says that once a trial is authorized, authorization under the Controlled Substances Regulations is required to permit the sale of psilocybin for clinical testing (Health Canada). For research more generally, the government says researchers will now be authorized through section 56(1) exemptions, as explained below.

How are trials listed, and how many are there?

Health Canada’s Canadian Clinical Trial Search Portal, launched on 29 July 2026, replaced its older Clinical Trials Database. It lists phase 1 to 3 trials in patients that Health Canada has approved since 1 April 2013 and links to international registries for eligibility and results. Health Canada says the portal is not used to recruit patients, and that site locations in registry data may appear before the sponsor has told Health Canada (Health Canada).

The registry ClinicalTrials.gov offers another view. On 4 October 2026 (data dated 2 October), a search for psilocybin as an intervention, with a Canadian location and a status of recruiting, not yet recruiting, enrolling by invitation or active but not recruiting, returned 29 studies. Fifteen were recruiting. By phase, 21 were listed as phase 2 only, four as phase 1 only, two as phase 3, one as combined phase 1 and 2, and one as not applicable. Seventeen listed a Toronto site, and others listed sites in Calgary, Kingston, Ottawa, Kelowna, Vancouver, Montreal and other cities (ClinicalTrials.gov).

Treat those counts as a snapshot. A single study can have several sites at different statuses, registry entries can lag, and a listing shows that a study exists, not that anyone can join it. Each protocol sets its own eligibility, and Health Canada advises people interested in a trial to talk to their health care provider (Health Canada).

Can trial participants take psilocybin at home?

Only in a narrow case. A Health Canada class exemption, effective 20 September 2025, covers participants in an authorized trial that involves at-home administration of psilocybin or MDMA. It lets them possess the quantity and form obtained from the qualified investigator and return unused drug. It requires the drug to stay in the form and amount authorized, to be secured against loss or theft, and any loss or theft to be reported within 10 days (Health Canada). It does not cover people outside such a trial.

What is the Special Access Program, and can it be used for psilocybin?

The Special Access Program lets practitioners request drugs that are not sold in Canada, for the treatment of a medical emergency. Health Canada reads that as a serious or life-threatening condition where conventional treatments have failed, are unsuitable or are unavailable. The request must be made by a practitioner entitled by their province or territory to treat patients with an unapproved prescription drug (Health Canada SAP page).

For psilocybin, that was not always possible. Regulatory amendments registered on 21 December 2021 removed the 2013 bar on restricted drugs in the SAP (Canada Gazette), and Health Canada says the ability to request psilocybin this way was restored in January 2022 (Health Canada). Health Canada’s SAP page, last modified on 8 April 2026, does not mention psilocybin itself (Health Canada SAP page).

What does a psilocybin request require?

• Only regulated health care practitioners who are authorized to treat patients with prescription drugs may file. Individuals cannot apply directly, and practitioners must also meet the practitioner requirements under the CDSA (Health Canada).
• The request must give enough evidence to support use of the drug for that patient’s condition. Health Canada assesses it case by case and says there is no guarantee it will be granted (Health Canada).
• If authorized, Health Canada issues a Letter of Authorization to the manufacturer, which lets it legally sell the specified quantity to the practitioner. A Canadian manufacturer must be a licensed dealer with psilocybin on its licence, and a foreign product must be imported by such a dealer with an import permit. The practitioner is responsible for identifying a manufacturer that can supply it (Health Canada).
• The practitioner must report outcomes and adverse reactions to Health Canada, keep accurate records and make sure the patient understands the risks, benefits and development status of the drug (Health Canada SAP page).

Who pays is not set by the program. The SAP page says the manufacturer determines the cost and that, in some cases, drugs released through the SAP are free (Health Canada SAP page).

What the SAP does not allow

Health Canada says the SAP and individual exemptions are not meant to encourage early use of unauthorized drugs or to get around the usual drug review process (Health Canada). In a 2021 notice about the change, it also said the SAP has no wait list because it is meant for emergency access, that health care professionals seeking psychedelics for training are not eligible, that the amendments did not signal decriminalization or legalization, and that advertising of unauthorized drugs is prohibited (Health Canada notice, 2021).

What changed on 1 October 2026?

The Controlled Substances Regulations (SOR/2025-242) came into force on 1 October 2026 (section 239). They repeal the Narcotic Control Regulations, the Benzodiazepines and Other Targeted Substances Regulations, the New Classes of Practitioners Regulations, an older exemption regulation, and Parts G and J of the Food and Drug Regulations (sections 237 and 238). Psilocybin and psilocin are listed in Part 1 of Schedule 4, the list of restricted drugs (Canada Gazette).

Three things in the published text matter here. First, for the SAP supply chain, a licensed dealer may sell or provide a restricted drug to a practitioner only if it has received a Letter of Authorization naming both it and the practitioner. A practitioner named in that letter may possess the drug, and may sell, provide or administer it to an individual they are treating in their professional capacity, once they have received a copy of the letter (sections 6, 58(2), 130(2) and 131(2)). Second, the government’s explanatory statement says the regulations incorporate six class exemptions. Its list of class exemptions that “will also be repealed” includes the one for psilocybin and MDMA in relation to an SAP authorization, and it says Health Canada will revoke those exemptions on the day the regulations take effect (Canada Gazette).

Third, for research, the same statement says there will be no separate research authorization pathway for restricted drugs, and that section 56(1) exemptions will be the mechanism by which Health Canada authorizes researchers to obtain any controlled substances for scientific purposes. It adds that Health Canada may consider an alternate authorization scheme in future (Canada Gazette). The Justice Laws consolidation we opened was current to 21 September 2026 (Justice Laws), so we relied on the Gazette text for what took effect.

Health Canada’s guidance has only partly caught up. Its psilocybin page was updated on 20 October 2026, and its clinical-trials section now names the Controlled Substances Regulations, but when we re-read it on 24 October it still said that once an SAP Letter of Authorization is issued, a section 56(1) class exemption allows certain parties, such as practitioners and hospital pharmacists, to conduct activities with psilocybin. The class exemption page (modified 17 December 2025) says it will be revoked on 1 October 2026, and the list of class exemptions (modified 24 September 2026) still showed it on 24 October (Health Canada; Health Canada class exemption; Health Canada list). The SAP page itself (modified 8 April 2026) does not mention psilocybin or the new regulations (Health Canada SAP page). The 20 October update does not explain how the SAP guidance now reads, and on 4 October we found no Health Canada notice dated after 1 October that did, so for current practice check those pages directly.

One gap we could not close: the earlier class exemption named hospitals, hospital employees, agents and pharmacists as well as practitioners and dealers. In the regulations we read, the possession rule for restricted drugs names licensed dealers, pharmacists outside hospitals and practitioners named in a Letter of Authorization, and the hospital provisions we found cover restricted drugs only for returns and destruction. We did not find text addressing hospital staff or agents in the SAP setting, and we are not saying none exists. A Canadian health lawyer could answer that.

What is a section 56 exemption, and can an individual get one?

Subsection 56(1) of the CDSA lets the Minister of Health exempt people, or classes of people, and substances from provisions of the Act for a scientific or medical purpose or when it is otherwise in the public interest. Each request is considered case by case (Health Canada). Health Canada describes an exemption as a formal document that authorizes specific activities that would otherwise be illegal, usually for a stated period and with conditions (Health Canada exemptions page).

For psilocybin tied to a medical condition, Health Canada lists factors it may weigh: whether trials or the SAP are available, the condition, the scientific evidence, whether conventional therapies were considered, practitioner support, public health and safety objectives, other laws and the risk of diversion. It asks for a letter of support from a medical practitioner showing that other legal routes were pursued or are not available or suitable (Health Canada).

In practice, that makes an individual exemption a fallback behind the other two routes. Health Canada says those routes should generally be pursued first (Health Canada). Its exemptions page sets target times for some applications (45 days for clinical studies and 70 for scientific research, once complete) but none for non-routine requests (Health Canada exemptions page). We found no published count of psilocybin exemptions granted, so we cannot say how often this route is used.

Do provinces have their own rules, such as Alberta’s?

Alberta does. We verified Alberta only and did not check other provinces or territories. Alberta’s Mental Health Services Protection Regulation includes Part 3 on psychedelic drug treatment services, and its list of designated psychedelic drugs includes psilocybin and psilocin alongside MDMA, ketamine, LSD, mescaline and DMT. Our copy of the regulation was current to 4 June 2026 (Alberta regulation).

What does Alberta require?

Alberta’s fact sheet says the requirements took effect on 16 January 2023. With certain exceptions, a provider of psychedelic-assisted therapy for psychiatric disorders must hold a licence under the Mental Health Services Protection Act and appoint a psychiatrist as medical director. A psychiatrist, or a physician consulting with one, must prescribe, and the drug must be given at a medical facility or clinic, with exceptions for end-of-life care. It cannot be self-administered or sold directly to the patient, and the patient must be monitored while in an altered state. Psychotherapy must be provided by people with set qualifications (Alberta fact sheet).

A licence is not required for an approved clinical research trial, but the investigator must report the trial to the province once a research ethics board approves it (Alberta licensing page). The fact sheet adds that the regulation applies to treating psychiatric disorders, not to research trials or to therapy for pain, palliative care or other illnesses (Alberta fact sheet). The Standards require a consent process that covers the experimental nature of the treatment and the evidence on its benefits and risks (Alberta Standards). Alberta publishes a directory of licensed providers; we list none here.

Does an Alberta licence make psilocybin legal?

Nothing we read says it does. The Alberta licensing page we opened does not mention federal law or Health Canada at all (Alberta licensing page). The Alberta Standards point the other way: they require a licensed provider to keep records of “any relevant authorization obtained to provide the psychedelic drug treatment services”, and they name authorizations under the federal Controlled Drugs and Substances Act and Food and Drugs Act as examples (section 27, Alberta Standards). That treats federal authorization as something separate from the provincial licence. Health Canada’s own list of three pathways does not include a provincial licence (Health Canada). We found no Alberta or federal sentence stating outright that a licence does or does not authorize the drug under the CDSA, so we do not make that claim. For any particular service, ask which federal route it relies on, and ask a Canadian lawyer if the answer matters to you.

What about clinics, retreats and storefronts that offer psilocybin “therapy”?

Not every offer is a route. Under Health Canada’s page, activities with psilocybin are illegal unless authorized, and the authorized routes are the three above (Health Canada). A service that supplies psilocybin outside a trial, an SAP authorization or an exemption is not one of the lawful routes in this article, however it describes itself. Federal rules also prohibit advertising of unauthorized drugs, including those authorized through the SAP (Canada Gazette, 2022), and the new regulations allow a controlled substance to be advertised only if it is not a restricted drug (section 235, Canada Gazette). For the penalties and the wider law, see our guide to whether magic mushrooms are legal in Canada.

Shroomverse sells mushroom products, which is why we state this plainly. Health Canada says the production, sale and possession of magic mushrooms are illegal in Canada (Health Canada), and this article does not suggest that anything we sell is a lawful route to therapy.

What is unsettled or unknown?

• How Health Canada’s psilocybin guidance now reads. Its psilocybin page was updated on 20 October 2026 but changed only its clinical-trials sentence, and it still describes the SAP class exemption as available. Its 2022 trial notice, its 2023 SAP notice on psychedelic-assisted psychotherapy and its SAP class-exemption page (modified 17 December 2025, still saying it will be revoked) all predate 1 October 2026. Check each page for updates.
• Whether the at-home trial exemption continues unchanged. It cites a provision in Part J of the Food and Drug Regulations, which was repealed, and the government’s statement does not mention it among the class exemptions ending on 1 October. We could not confirm how it applies now. Health Canada’s list of class exemptions, updated 24 September 2026, still listed it.
• How researchers obtain psilocybin in practice under the new regulations. The separate Part J research authorization is gone and section 56(1) exemptions are the stated mechanism for research; for clinical trials, Health Canada’s page now names an authorization under the Controlled Substances Regulations, but the published text of the Regulations does not mention clinical trials, so we could not tell which provision it means.
• How often the SAP and individual exemptions are granted for psilocybin. We found no official figures on the pages we read.
• Whether a provincial framework outside Alberta exists. We did not verify other provinces or territories.
• Whether psilocybin will be approved as a drug. Health Canada’s page says none is approved. See what a US filing might mean for Canada for what we could verify.

How can you check the current position?

Start with the Health Canada psilocybin and psilocin page, the Special Access Program page and the list of class exemptions, each linked in our sources. Then ask a regulated health care practitioner about your own situation. Health Canada encourages people seeking help for these conditions to talk to their health care provider (Health Canada). For a legal question, ask a Canadian lawyer.

Shroomverse sells mushroom products. This article is general information about the law and clinical research. It is not medical or legal advice, and it does not recommend any product, provider or clinic.